{"schema_version":"secwatch.filing_event.v1","accession":"0001567264-25-000040","form_type":"8-K","ticker":"INTS","cik":"0001567264","company_name":"INTENSITY THERAPEUTICS, INC.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.809199+00:00","generated_at":"2026-05-21T15:53:52.193162+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Intensity Therapeutics pauses Phase 3 sarcoma study enrollment; Q1 net loss $3.3M, cash $0.9M","bullets":["Paused new site activations and enrollment in Phase 3 INVINCIBLE-3 sarcoma study due to funding constraints; 23 patients enrolled.","April 2025 public offering raised $2.35M gross ($1.9M net) to prioritize Phase 2 INVINCIBLE-4 breast cancer trial.","Q1 2025 net loss $3.3M (vs $4.6M Q1 2024); cash and equivalents $0.9M as of March 31, 2025.","Eight Swiss sites activated in INVINCIBLE-4; EMA authorized study in France with Unicancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001567264-25-000040","json":"https://secwatch.observer/filing/0001567264-25-000040.json","markdown":"https://secwatch.observer/filing/0001567264-25-000040.md","text":"https://secwatch.observer/filing/0001567264-25-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567264/000156726425000040/0001567264-25-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567264/000156726425000040/intensity-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T15:53:52.193162+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}